Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway

[Image: see text] Temozolomide (TMZ), as the first-line chemotherapeutic agent for the treatment of glioblastoma multiforme (GBM), often fails to improve the prognosis of GBM patients due to the quick development of resistance. The need for more effective management of GBM is urgent. The aim of this...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ACS Omega
Autors principals: Xiong, Jinbiao, Guo, Gaochao, Guo, Lianmei, Wang, Zengguang, Chen, Zhijuan, Nan, Yang, Cao, Yiyao, Li, Ruilong, Yang, Xuejun, Dong, Jun, Jin, Xun, Yang, Weidong, Huang, Qiang
Format: Artigo
Idioma:Inglês
Publicat: American Chemical Society 2021
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7906592/
https://ncbi.nlm.nih.gov/pubmed/33644550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.0c05399
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars